Thesis
TTX-MC138's Phase 2a ctDNA clearance readout in colorectal MRD will determine whether a miRNA-10b inhibitor can become a registrational asset
TTX-MC138 is a lipid nanoparticle-delivered anti-miR-10b oligonucleotide targeting Stage I–III colorectal cancer patients with detectable ctDNA after curative-intent therapy, a high-recurrence MRD population with no approved standard of care. The thesis turns on whether the Phase 2a single-arm trial demonstrates statistically meaningful ctDNA clearance sufficient to support an FDA-agreed registration design. The primary competitive and regulatory risk is that ctDNA clearance as a surrogate endpoint lacks regulatory precedent as a registration-enabling primary endpoint, and approved adjuvant checkpoint inhibitors like pembrolizumab are actively expanding into earlier-stage colorectal settings.
Focus
Phase 2a TTX-MC138 colorectal: ctDNA clearance readout
2027
Bull
A positive outcome would be a statistically and clinically meaningful rate of ctDNA clearance (MRD conversion to negativity) in Stage 1–3 colorectal adenocarcinoma patients across the N=45 cohort, with a durable signal that benchmarks favorably against the natural MRD clearance rate. This would validate miRNA-10b inhibition as a mechanism capable of eradicating residual disease, de-risking the biology and enabling design of a registrational trial with ctDNA clearance or DFS as the endpoint.
Bear
The most likely failure mode is insufficient ctDNA clearance — either too few patients achieving MRD negativity or responses that are transient and not durable over the 12-cycle treatment period — failing to differentiate from the background spontaneous clearance rate in early-stage colorectal MRD. A secondary risk is pharmacodynamic inadequacy: miRNA-10b inhibition may not translate from the solid tumor suppression seen in Phase 1a (stable disease in advanced patients) to actual MRD eradication in the micrometastatic setting, where a fundamentally different biological threshold applies.
Unlock the full thesis for RNAZ.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.